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Atherosclerosis is considered as a chronic disease of arterial wall, with a strong
contribution of inflammation. Dendritic cells (DCs) play a crucial role in the initiation
of proatherogenic inflammatory response. Mature DCs present self-antigens thereby
supporting differentiation of naïve T cells to effector cells that further propagate
atherosclerotic inflammation. Regulatory T cells (Tregs) can suppress proinflammatory
function of mature DCs. In contrast, immature DCs are able to induce Tregs and
prevent differentiation of naïve T cells to proinflammatory effector T cells by initiating
apoptosis and anergy in naïve T cells. Indeed, immature DCs showed tolerogenic and
anti-inflammatory properties. Thus, DCs play a double role in atherosclerosis: mature DCs
are proatherogenic while immature DCs appear to be anti-atherogenic. Tolerogenic and
anti-inflammatory capacity of immature DCs can be therefore utilized for the development
of new immunotherapeutic strategies against atherosclerosis.
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INTRODUCTION
Dendritic cells (DCs) were first described by Steinman and Cohn
(1973). DCs are a heterogeneous group of professional antigen-
presenting cells (APCs). DCs differentiate from precursors cir-
culating in the bloodstream (Sorg et al., 1999). The precursors
can be delivered by blood to the target non-lymphoid organ or
tissue, in which they become immature DCs. Immature DCs
express on their surface integrin alpha X (CD11c) (Sorg et al.,
1999). However, costimulatory molecules CD80/CD86 essential
for T cell activation are not or expressed or produced at very
low levels (Cocks et al., 1995) (Figure 1). Indeed, immature DCs
can capture antigens but are not able to stimulate naïve T cells.
From the target tissue, immature DCs in turn migrate to lym-
phoid organs such as spleen and lymph nodes in which they
differentiate into mature DCs. The maturation is accompanied
by enhanced expression of costimulatory molecules CD80/86 and
CD40, antigen-presenting molecules (MHC class I and II), and
Abbreviations: APCs, antigen-presenting cells; apo (Apo), apolipoprotein;
C. pneumonia, Chlamydia pneumonia; CCL, CC-motif chemokines; CCR,
chemokine receptors; CD, cluster of differentiation; cDCs, myeloid DCs; CTLA-4,
cytotoxic T-lymphocyte antigen-4; DC, Dendritic cell; DCs, Dendritic cells; DNA,
deoxyribonucleic acid; FoxP3, forkhead box P3; IDO, indoleamine 2,3-dioxigenase;
IL, interleukin; iTregs, FoxP3+ Tregs; LDL, low density lipoprotein; LDLR, LDL
receptor; LFA-1, lymphocyte function-associated antigen 1; M-CSF, macrophage-
colony stimulating factor; MDA-LDL, malonaldehyde-modified LDL; MHC, major
histocompatibility complex; NKT cells, natural killer T cells; NZW, New Zealand
White; oxLDL, oxidized LDL; pDCs, plasmacytoid DCs; PDL-1, programmed death
ligand 1; Scid, severe combined immunodeficiency syndrome; TGFßRII, tumor
factor growth-ß receptor II; Th, T helper; Tr1, type 1 regulatory T cells; Tregs,
regulatory T cells; VSMCs, vascular smooth muscle cells.
adhesion molecules (CD11a, CD50, CD54, CD86). Mature DCs
can contact and present antigens to naïve T cells, which in turn
differentiate into effector T cells such T helper 1 (Th1) or 2 (Th2)
cells. DCs also secrete interleukin (IL)-12, a proinflammatory
cytokine that directs differentiation of naïve T cells to effector T
cells (Kubin et al., 1994). Some immature DCs exhibit tolerogenic
properties through the induction of regulatory T cells (Tregs) and
suppression of naïve T cell activation (Steinman et al., 2003).
Atherosclerosis is a chronic inflammatory disease, with a
pathogenic immune response driven by T lymphocytes (Hansson
and Hermansson, 2011). Due to their critical role in effector
T cell differentiation from naïve T cells, it is not surprisingly
that DCs are found to be the key players in the proinflam-
matory response at the atherosclerotic plaque. The discovery
of the presence of DCs in the intima of normal arteries and
atherosclerotic lesions led to a suggestion that DCs might play
an important role in the development of atherosclerotic lesions
(Bobryshev and Lord, 1995a,b). An entire network of HLA-DR-
expressing cells was eventually found to exist in the intimal space
of normal human aortas (Bobryshev et al., 2012), suggesting
their potential role in the regulation of vascular homeostasis.
The architectonics of this network may be different in various
aortic segments thereby predicting putative atherosclerosis-prone
and atherosclerosis-resistant regions of the visually normal aorta
(Bobryshev and Lord, 1995a).
The involvement of DCs in atherogenesis was then proven by
experimental findings on two rodent atherosclerosis models such
as apolipoprotein (apo) E-null and LDL receptor (LDLR)-null
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FIGURE 1 | Immature and mature DCs. Immature DCs arise from DC
precursors that circulate in the blood. From the blood, DC precursors may
reach the target tissue where they transform into immature DCs. The major
function of immature DCs is the capture of antigens. Immature DCs
capturing antigens may then migrate into lymphoid tissues such as the
spleen and lymph nodes where they further differentiate becoming mature
DCs. Mature DCs are capable to efficiently present captured antigens to
naïve T cells. DC maturation is characterized by the up-regulation of
expression of molecules responsible for antigen presentation such as MHC
class II and CD80/CD86. After antigen recognition, naïve T cells differentiate
into effector T cells. Differentiation of naïve T cells to effector cells may
occur upon cell-cell contacts between a DC and a naïve T cell and via
proinflammatory cytokine IL-12 secreted by mature DCs. Immature DCs
lacking sufficient expression of antigen-presenting molecules cause anergy
and apoptosis of naïve T cells. Immature DCs possess tolerogenic
properties by inducing Tregs through cell-to-cell contact with naïve T cells
and through secreting anti-inflammatory cytokines such as IL-10 and TGF-β.
Since immature DCs are capable to induce Tregs and inhibit the
inflammatory reaction in the atherosclerotic plaque, the development of
strategies for the induction of tolerogenic DCs is of great therapeutic
promise.
mice (Bobryshev et al., 1999; Paulson et al., 2010). Transfer
of oxidized low density lipoprotein (oxLDL)-reactive T cells to
ApoE-null severe combined immunodeficiency syndrome (Scid)
mice are more effective in plaque presentation compared to the
transport of non-specific T cells to an antigen derived from a
lesion (Zhou et al., 2006), thereby suggesting on the involve-
ment of those cells in presenting antigens in disease progression.
DCs were observed in atherosclerotic lesions of apoE- (Bobryshev
et al., 1999, 2001) and LDLR-null mice (Paulson et al., 2010),
and these cells were not present in the plaques just accidentally
but accumulated and contributed to the intraplaque inflamma-
tion and progression of the coronary atheroma (Ludewig et al.,
2000; Hjerpe et al., 2010).
Since the identification of DCs in the arterial wall (Bobryshev
and Lord, 1995a,b), the functional significance of this cell type
has been intensely studied and various issues of the involvement
of DCs in atherogenesis have been discussed in a number of
reviews (Bobryshev, 2000, 2005, 2010; Cybulsky and Jongstra-
Bilen, 2010; Niessner and Weyand, 2010; Koltsova and Ley, 2011;
Manthey and Zernecke, 2011; Van Vré et al., 2011; Butcher and
Galkina, 2012; Feig and Feig, 2012; Takeda et al., 2012; Alberts-
Grill et al., 2013; Cartland and Jessup, 2013; Grassia et al., 2013;
Koltsova et al., 2013; Subramanian and Tabas, 2014). It is impor-
tant to note here that functions of DCs in human arteries are
still practically unknown and that the accumulated information
about functions of DCs in atherosclerosis is obtained in exper-
imental studies. However, in contrast to the intima of human
arteries which contains the nets of DCs (Bobryshev and Lord,
1995a; Bobryshev, 2000), the intima of large arteries in animal
models of atherosclerosis consists of the endothelium that is sepa-
rated from the internal elastic membrane by just a narrow layer of
free-of-cell matrix. In humans, the activation of resident vascular
DCs occurs in the very earlier stage of atherosclerosis (Bobryshev
and Lord, 1995a; Bobryshev, 2000), whereas the accumulation of
DCs in the arterial intima in animal models of atherosclerosis
occurs as a result of the penetration of DCs or DC precursors from
the blood stream, parallel with the development of atherosclerotic
lesions (Bobryshev et al., 1999, 2001). Likewise, little is known
about the peculiarities of functions of immature DCs vs mature
DCs in human atherosclerosis (Bobryshev, 2010).
Accumulated evidence obtained in experimental studies indi-
cates that, depending on the maturation stage, DCs play a double
role in atherogenesis: mature DCs display proatherogenic fea-
tures whereas immature DCs seem to be anti-atherogenic. In
this review, we highlight a double role of DCs in atherogene-
sis. Obviously, further studies are needed in order to translate
knowledge obtained in experiments to human atherogenesis.
DC SUBSETS AND THEIR ROLE IN ATHEROSCLEROSIS
There are several subsets of DCs can be distinguished includ-
ing conventional (myeloid) DCs (cDCs), plasmacytoid DCs
(pDCs), and inflammatory DCs (Shortman and Naik, 2007).
Inflammatory DCs cannot be found in the steady state but emerge
after inflammatory stimuli. Unlike cDCs, pDCs are weak in anti-
gen presentation (Shortman and Naik, 2007). However, pDCs are
potent inducers of the interferon (IFN) type I response against
viral and bacterial infections (Villadangos and Young, 2008). Choi
et al. (2011) have proposed markers to discriminate DCs sub-
sets in murine atherosclerosis but the function of different subsets
remains to be elucidated. Although the presence of both subtypes
of DCs is known in humans, the most reliable information about
the functions of cDCs and pDCs are obtained in animal studies
(Shortman and Naik, 2007; Villadangos and Young, 2008; Busch
et al., 2014).
Normally, vascular DCs were proposed to contribute to main-
taining tolerance to self-antigens; in proatherosclerotic condi-
tions, activated vascular DCs may present self-antigens to T cells
and promote inflammatory response in the plaque (Niessner
and Weyand, 2010). Both pDCs and cDCs were found in the
shoulder region of carotid artery lesions (Niessner et al., 2006).
pDC were detected in human and mouse atherosclerotic lesions
(Niessner et al., 2006; Niessner and Weyand, 2010; Daissormont
et al., 2011). pDCs were shown to produce large amount of
IFNα, a potent regulator of T cells, that might lead to the unsta-
ble plaque phenotype (Niessner et al., 2006). In the LDLR-null
mice, pDC depletion, in contrast, led to T cell accumulation
and promoted atherosclerotic lesion formation (Niessner et al.,
2006). However, in a recent study, specific depletion of pDC in
aortas and spleen of apoE-deficient mice was associated with
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significantly reduced atherosclerosis (Macritchie et al., 2012). In
another study, the construction of self-response complexes loaded
with patient’s DNA and anti-microbial peptides enhanced early
plaque formation in apoE-null mice (Döring et al., 2012).
pDS and IFNs isolated from the plaque are involved in the
maturation of DCs and macrophages (Döring and Zernecke,
2012). Indeed, these findings suggest for a rather proatherogenic
role of pDCs (Döring and Zernecke, 2012) that should be further
elucidated. Apart from the existence of cDCs and pDCs, lesion
DCs may also arise from the blood-derived monocytes that
infiltrate the intima (Randolph et al., 1998). Several studies
in mice and humans have addressed this issue (Jongstra-
Bilen et al., 2006; Dopheide et al., 2012). Choi et al. (2011)
observed in murine aorta new subtype of monocyte-derived
DCs (CD11chighMHCIIhighCD11b−CD103+). According
to Choi et al. (2011), DCs in murine atherosclerosis are
primarily presented by two subsets: macrophage-colony stim-
ulating factor (M-CSF)-dependent monocyte-derived DCs
(CD14+CD11b+DC−SIGN+), and classical Flt3-Flt3L signaling-
dependent cells (CD103+CD11b−). Although there might be
a wide spectrum of DCs subsets in the intima of arteries, the
functioning of DCs largely depends on the maturation stage
(Butcher and Galkina, 2012).
Immature CD1a+S100+lag+CD31−CD83−CD86− DCs were
found in the normal aortic intima of young individuals (Millonig
et al., 2001). HLA-DR+CD1a+S-100+ DCs were found in the
normal human aorta, carotid arteries and in atherosclerotic
plaques (Bobryshev and Lord, 1995a; Bobryshev, 2000). DCs
are also located in the under-plaque media and in the adven-
titia around the vasa vasorum in the shoulder regions of the
atherosclerotic lesion (Bobryshev and Lord, 1998). Mature CD83
positive DCs were observed in rupture-prone plaque regions
in human carotid arteries (Yilmaz et al., 2004). These studies
showed that heterogeneity of the DC population seems to increase
progressively during the plaque progression.
There are several pathways by which DC numbers can be
increased within atherosclerotic plaques. DCs and their precur-
sors could infiltrate plaques migrating from the bloodstream
by a chemokine- and adhesion molecule-dependent pathway
(Niessner and Weyand, 2010). DCs can migrate to advanced
lesions from the adventitia during vasa vasorum-associated neo-
vascularization (Bobryshev and Lord, 1998). The third way is
associated with monocytes that penetrate the intima at early
atherosclerosis steps in order to differentiate into macrophages or
DCs in response to inflammatory stimuli (Randolph et al., 1998).
Therefore, inhibition of the activation and recruitment of increas-
ing numbers of activated DCs may be important in preventing
lesion formation.
ROLE OF DCs IN INDUCTION OF T-CELL MEDIATED
PROINFLAMMATORY RESPONSE IN THE ATHEROSCLEROTIC
LESION
As mentioned above, immature DCs having
CD11c+CD80−/lowCD86−/low phenotype are tolerogenic
DCs responsible for capturing antigens. These DCs might play
anti-inflammatory role because they may induce apoptosis or
anergy in naïve T cells responding to self-antigens (Kushwah
and Hu, 2011). By capturing antigens, immature DCs differ-
entiate into mature DCs. Mature CD11c+CD80+CD86+ DCs,
in contrast, may play a proinflammatory role by presenting
self-antigens to naïve T cells, which then differentiate to effector
T cells, and by secreting inflammatory cytokines such as IL-12.
During the late stage of monocyte differentiation, oxLDL pro-
mote maturating DCs into IL-12-producing cells, which further
support inflammatory reaction in the plaque (Perrin-Cocon
et al., 2001). Furthermore, in LDLR−/− mice, resident intimal
DCs were shown to rapidly accumulate oxLDL and initiate
nascent foam cell lesion formation (Paulson et al., 2010). By pre-
senting antigens, mature DCs and macrophages induce adaptive
T-cell mediated immune response (Paulson et al., 2010; Choi
et al., 2011). However, there is conflicting evidence on the role of
oxLDL (and hyperlipidemia) on the maturation and function of
DCs (Perrin-Cocon et al., 2001, 2013; Ge et al., 2011; Nickel et al.,
2012; Peluso et al., 2012). A recent study by Hermansson et al.
(2011) revealed that native LDL can also be recognized by DCs.
In shoulders of human vulnerable atherosclerotic plaques,
CD83+ DCs were identified in the vicinity to CD40L+ T cells
(Yilmaz et al., 2006). This population of DCs secrete CC-motif
chemokines (CCL)19 and CCL21 capable to enhance recruit-
ment of naive lymphocytes into atherosclerotic vessels (Erbel
et al., 2007) (Figure 2). pDCs responded to pathogen-derived
motifs and CpG-containing oligodeoxynucleotides by elevated
production of IFN α that recruits naïve T cells, which then
differentiate into cytotoxic CD4+ effector T cells capable to effec-
tively kill vascular smooth muscle cells (VSMCs) (Niessner et al.,
2006). Therefore, in the atherosclerotic lesion, pDCs are able
to sense microbial motifs and accelerate activity of cytotoxic
T-lymphocytes thereby providing a link between severe immune-
mediated atherosclerotic complications and infections. CD4+ T
cells derived from atherosclerotic plaques are capable to recog-
nize oxLDL, heat shock proteins (HSP)60/65, and other antigens
from pathogenic microorganisms such as Chlamydia pneumonia,
FIGURE 2 | Cytokines and chemokines produced by mature DCs in the
atherosclerotic vessels. DC-derived cytokines mostly possess
proinflammatory and proatherogenic properties. Chemokines secreted by
mature DCs stimulate chemotaxis of a variety of immune cells to attract
them to the atherosclerotic lesion.
www.frontiersin.org May 2014 | Volume 5 | Article 196 | 3
Chistiakov et al. Dendritic cells in atherogenesis
which are supposed to be candidate self-antigens for atherogen-
esis (Stemme et al., 1995; Benagiano et al., 2005; Mandal et al.,
2005). Stephens et al. (2008) showed the ability of a self-peptide
Ep1.B derived from human apoE to induce differentiation of
monocytes to DCs, thereby suggesting for a putative mecha-
nism of self-antigen-mediated induction of inflammation at early
stages of atherosclerosis. Immunochemical staining revealed the
presence of C. pneumonia in DCs derived from atherosclerotic
plaques thus supporting again a likely role of DCs as a bridge
linking the pathogen-induced proinflammatory responses to the
induction of atherogenesis (Bobryshev et al., 2004).
CROSSTALKS BETWEEN DCs AND TREGS IN
ATHEROSCLEROSIS
Tregs are involved in the activation, maturation, and function of
DCs (Steinman and Banchereau, 2007; Chistiakov et al., 2013).
By CTLA-4-dependent inhibition of CD80/CD86 expression in
proatherogenic DCs, Tregs are capable to suppress their antigen-
presenting activity (Onishi et al., 2008). CTLA-4 is expressed
only in stimulated Tregs including forkhead box P3 (Foxp3)+
Tregs. Tregs. CTLA-4 interacts with B7-1 (CD80) and B7-2
(CD86) molecules broadly presented in the surface of DCs and
macrophages and conducts an inhibitory signal to DCs decreas-
ing expression of both costimulators (Bour-Jordan et al., 2011).
Through binding to CD80/CD86, CTLA-4 could initiate produc-
tion of indoleamine 2,3-dioxigenase (IDO) in DCs. IDO converts
tryptophane to kinurenine that is a potent immunosuppressant
capable to induce de novo formation of Tregs from naïve T cells in
the local environment (Fallarino et al., 2003).
The second inhibitory pathway by which Tregs interacting
with mature DCs can down-regulate antigen presentation is
CD80/CD86 trogocytosis, which is a process of intercellular trans-
fer of cell surface proteins and outer membrane fragments (Gu
et al., 2012). Trogocytosis is mediated with CD28, CTLA-4, and
programmed death ligand 1 (PDL-1) and involves CD80/CD86
removal from the surface of DCs therefore increasing the
inhibitory capacity of Tregs. Tregs from the CTLA-4-knockdown
mice failed to suppress CD80/CD86 production suggesting for a
key role of CTLA-4 in the suppression of CD80/CD86 expression
in antigen-presenting mature DCs (Gao et al., 2011). CTLA-4
binding to CD80/CD86 on the surface of DCs has a major role
in inducing tolerance (Oderup et al., 2006). Indeed, CTLA-4
may represent a promising target for treatment of atherosclero-
sis by enhancing the inhibitory activity of Tregs or increasing
suppression of effector T cells (Gotsman et al., 2008).
T-cell adhesion molecule lymphocyte-associated antigen 1
(LFA-1) mediates contact between an antigen-presenting DC and
a Treg (Onishi et al., 2008). Tregs maintain the CD80/CD86-
suppressing capacity even if potent DC-maturating stimuli are
present. Thus, Tregs may effectively block proinflammatory sig-
nals from antigen-presenting DCs to naive T-lymphocytes via
binding to immature DCs followed by CTLA-4/LFA-1-mediated
down-regulation of CD80/CD86 production in DCs. Indeed,
DCs can influence function of Tregs through their inhibition
or stimulation. Proatherosclerotic CCL17+CD11+ DCs capa-
ble to down-regulate Tregs have been found (Weber et al.,
2011). Also, a population of atheroprotective monocyte-derived
CD11highMHChighCD11b−CD103+ DCs which are able to
induce Tregs in the lesion was identified (Choi et al., 2011).
Lievens et al. (2013) have constructed an apoE-null mouse har-
boring a transgene whose expression causes inactivation of tumor
factor growth-β receptor II (TGFβRII)-dependent signaling in
CD11-positive DCs. Prevention of TGFβRII signaling mechanism
results in shifting of CD11c+CD8− DCs toward the more proin-
flammatory CD11c+ population, which resulted in enhanced
T cell activation and maturation and advanced atherosclerosis.
These observations suggest for an anti-atherogenic role of TGFβ
signaling that may be responsible for maintaining immunosu-
pressory properties in DCs and preventing their differentiation
toward the proinflammatory phenotype.
Most tolerogenic DCs are immature and have
CD86−CD80−CD40−MHCII− phenotype (Maldonado and
von Andrian, 2010). These cells can induce Tregs by direct
interaction or through production of cytokines TGF-β and IL-10.
IL-10 mediates differentiation of peripheral T-cells to Tregs.
Tolerogenic DCs producing IL-10 are implicated in the induction
of IL-10-producing type 1 regulatory T cells (Tr1) (Figure 3).
Tregs and DCs interact to each other via CCL17 and CCL22, and
their receptors, chemokine receptors (CCR) 4 and 8 Iellem et al.,
2001; Weber et al., 2011). These receptors are produced on the
surface of Tregs and may bind DCs-secreted CCL17 and CCl22.
CCL22 induction on tolerogenic CDs results in the recruitment
of Tregs in the site of inflammation including the atherosclerotic
lesion. The CCR4-deficient mice showed significantly decreased
expression of IDO in DCs from mesenteric lymph nodes
(Onodera et al., 2009). This finding could suggest for a role of
IDO in the regulation of activating effect of CCL22 and CCR4
on Tregs induction. Overall, these observations show that the
immunoregulating enzyme IDO has a crucial role in regulating
reciprocal DCs-Tregs contacts mediated by B7/CTLA-4 and
CCL22/CCR4 in atherogenesis. Therefore, inducing tolerogenic
DCs may be important for enhancing protective effects of Trgs
against atherosclerosis.
PROGRESS TOWARD THE CLINIC
In addition to the above suggestion that the development of
strategies for the induction of tolerogenic DCs may be of great
therapeutic promise, it is important to noting here that the accu-
mulated evidence has showed that, indeed, DCs might be used for
anti-atherosclerosis immunotherapy. The support for this view
has come from a number of studies performed on mouse models
of atherosclerosis in which the function of DCs was manipu-
lated (Zhou et al., 2006; Hjerpe et al., 2010; Daissormont et al.,
2011; de Jager and Kuiper, 2011; Döring et al., 2012; Macritchie
et al., 2012). Currently, there is no sufficient evidence to state
that cDCs are proatherogenic and that pDCs are atheroprotec-
tive. Nevertheless, based on the assumption that cDCs action
is rather proatherogenic whereas pDCs might be atheroprotec-
tive, the inhibition of cDCs can induce atheroprotective immune
reactions (Bobryshev, 2010).
DCs are thought nowadays as a valuable instrument for
atherosclerosis immunotherapy (Van Vré et al., 2011; Takeda
et al., 2012; Grassia et al., 2013; Van Brussel et al., 2013, 2014).
DCs could also induce tolerance against antigens that are innate
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FIGURE 3 | Crosstalk between immature and mature DCs. Mature DCs
could attract immature DCs and DC precursors to the site of inflammation
(i.e., to the atherosclerotic plaque) through secretion of chemokines CCL2
and CCL14. Immature DCs in turn migrate to the plaque where they are
activated by the local proinflammatory microenvironment to differentiate
preferentially to inflammatory mature antigen-presenting DCs. Local mature
DCs could contribute to the proinflammatory DC maturation by secreting
inflammatory cytokines IL-1β, IL-6, and TNF-α. Natural FoxP3+CD4+CD25+
T cells induce conversion of immature DCs to tolerogenic DCs. Chemokine
CCL18 produced by immature DCs stimulates tolerogenicity through the
induction of IL-10-mediated expression of IDO in DCs. IFN-γ is able to
contribute to the formation of tolerogenic DCs by inhibiting expression of
Th17-inducing osteoprotegerin and stimulating IL-27 production. IL-27
suppresses production of Th17-polarizing cytokines IL-1β, IL-6, and IL-23
from DCs and activates expression of IL-10, IL-21, and ICOS in naïve CD4+ T
cells that drives induction of IL-10 producing Tregs (Tr1). IL-10 produced by
tolerogenic DCs induces Tr1 cells through the ILT2/ILT4-mediated signaling
mechanism. TGF-β1 secreted by tolerogenic DCs could induce expression
of FoxP3 and IDO in CD4+CD25− naive T cells that promotes their
conversion into inducible FoxP3+ Tregs (iTregs). Chemokines CCL17 and
CCL22 secreted by tolerogenic CDs attract Tregs to the atherosclerotic
lesion where Tregs could suppress immunomodulatory properties of
proinflammatory antigen-presenting CDs and prevent differentiation of
immature CDs to inflammatory subsets of mature DCs.
to the body (Steinman et al., 2003; Palucka and Banchereau,
2012). DCs can be used as natural adjuvants for the induction of
antigen-specific T-cell responses (Caminschi et al., 2012; Palucka
and Banchereau, 2012; Yamanaka and Kajiwara, 2012). Anti-
atherosclerotic immunotherapy with the utilization of DCs may
be the same or somewhat different from those approaches that
are currently used for cancer immunotherapy (Caminschi et al.,
2012; Palucka and Banchereau, 2012; Yamanaka and Kajiwara,
2012). It is essential to stress that remarkable results have been
achieved in treatment of cancer patients whenDCs loaded with an
antigen were used as vaccines for improving the host anti-cancer
immune response (Palucka and Banchereau, 2012; Yamanaka
and Kajiwara, 2012). One of approaches involves an ex vivo
treatment of DCs with an appropriate antigen, followed by fur-
ther return of the antigen-treated DCs (so called “pulsed” DCs)
back to the patient’ blood. A similar approach can be evalu-
ated for the use in atherosclerosis immunotherapy (Bobryshev,
2001).
One of the main challenges for developing of effective vaccines
for atherosclerosis relates to the selection of a specific antigen
to target. Several strategies have been offered; So far, vaccina-
tion strategies have been based on targeting of lipid antigens
and inflammation-derived antigens (de Jager and Kuiper, 2011).
Amongst the used approaches, immunization of hypercholes-
terolemic animals with oxLDL or specific epitopes of ApoB100
has been reported to inhibit atherosclerosis (Nilsson et al., 2007;
van Leeuwen et al., 2009). Perhaps, DCs pulsed with autologous
modified LDL or immunogenic components of autologous mod-
ified LDL could be used as well for immunization; this would
allow avoiding side effects of direct vaccination with oxLDL
(Bobryshev, 2010). Apart from pulsation with modified LDL,
DCs can be also treated ex vivo through culturing with a total
extract of the “own” atherosclerotic lesion, for instance, from sub-
jects who underwent carotid enadarterectomy or other vascular
interventions (Bobryshev, 2001). An obvious advantage of such
approach, in which a patient is vaccinated with its “own” DCs
pulsed by patient’s “own” antigens is the specificity: the event of
pulsation of DCs wouldmimic the processes that occur in plaques
of the patient. This approach can be considered as an example of
“personalized” medicine (Hamburg and Collins, 2010).
Although the idea to use of DCs for vaccination in atheroscle-
rosis is widely discussed (de Jager and Kuiper, 2011; Van Vré
et al., 2011; Cheong and Choi, 2012; Döring and Zernecke,
2012; Takeda et al., 2012; Van Brussel et al., 2013, 2014), exper-
imental studies that already utilized DCs for immunotherapy of
atherosclerosis are still quite limited (Habets et al., 2010; Hjerpe
et al., 2010; van Es et al., 2010; Hermansson et al., 2011; Pierides
et al., 2013). Currently, an immunotherapeutic strategy based on
the isolation of autologous DCs, subsequent loading with appro-
priate antigen(s) ex vivo (e.g., immunogenic epitopes of modified
LDL or a total plaque extract), and return to the host blood is
under development (Habets et al., 2010; Hjerpe et al., 2010; van
Es et al., 2010; Hermansson et al., 2011; Pierides et al., 2013)
(Table 1). The future of this strategy is consisted in the develop-
ment of atheroprotective vaccines on the basis of patient’s DCs
(Van Brussel et al., 2013).
Another promising strategy involves studying properties of
various immune cells interacting with DCs in order to develop
DCs-based vaccines capable to modulate those immune cells
in atherosclerosis. For example, van Es et al. (2010) used DCs
expressing a FoxP3 transgene, a master regulator in the develop-
ment and function of Tregs, to induce the anti-FoxP3 immune
response in LDLR-null mice. The anti-FoxP3-specific immunity
resulted in partial depletion of FoxP3-positive Tregs in sev-
eral organs, early induction of proatherogenic inflammation and
advanced atherosclerotic plaque progression. This observation
indeed suggests for the crucial atheroprotective properties of
Tregs.
An adoptive transfer of natural killer T (NKT) cells from
Vα14Jα18 T-cell receptor transgenic mice caused significant pro-
gression in aortic atherosclerosis in recipient immune-deficient
RAG-null LDLR-null mice (VanderLaan et al., 2007). Serum
derived from the recipient animals then induced activation of
Vα14Jα18 T-cell receptor-expressing hybridoma by DCs. This
finding shows proatherogenic properties of CD1d-dependent
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Table 1 | Examples of anti-atherosclerosis immunization of experimental atherosclerosis animal models involving LDL or its related peptides.
Animals Immunogenes Effect on atherosclerosis References
LDLR-null rabbits MDA-LDL 1.5-fold decrease in the extent of aortic
lesions
Palinski et al., 1995
NZW rabbits on fat-rich diet Native LDL or Cu2+-oxidized LDL Reduction in aortic plaques by 74% (native
LDL) and 48% (oxLDL)
Ameli et al., 1996
LDLR-null mice Native LDL or MDA-LDL Reduction in aortic sinus plaques by 46.3%
(MDA-LDL) and 36.9% (native LDL)
Freigang et al., 1998
ApoE-null mice MDA-LDL 2.1-fold decrease in the size of aortic sinus
lesions
George et al., 1998
ApoE-null mice apoB-100 peptides (p143 and
p210)
Reduction in aortic atherosclerosis by 60% Fredrikson et al., 2003
ApoE-null mice Native LDL 1.7-fold decrease in the size of aortic sinus
lesions
Chyu et al., 2004
ApoE-null mice apoB-100 peptides (p143 and
p210)
Reduction of aortic atherosclerosis by 40%
and plaque inflammation by 89% (p210)
Chyu et al., 2005
LDLR-null mice oxLDL or MDA-LDL Attenuation of the initiation (30–71%) and
progression (45%) of atherogenesis
van Puijvelde et al., 2006
LDLR-null apoB-transgenic mice apoB-100 peptides (p45 and p210) Reduction of aortic atherosclerosis by 66%
(p45) and 59% (p210)
Klingenberg et al., 2010
ApoE-null mice apoB peptide (p210) Reduction in aortic sinus lesion size by 35% Fredrikson et al., 2008
ApoE-null mice DCs pulsed with MDA-LDL Significant increase in aortic lesion size and
inflammation
Hjerpe et al., 2010
LDLR-null mice DCs pulsed with Cu2+-oxidized
LDL
87% decrease in carotid artery lesion size
and increase in plaque stability
Habets et al., 2010
LDLR-null mice DCs transfected with FoxP3
mRNA
Reduction of Foxp3+ Tregs cells in several
organs; increase in initial atherosclerotic
lesion formation and in plaque cellularity
van Es et al., 2010
LDLR-null apoB100-transgenic mice DCs loaded with apoB-100 70% reduction in aortic lesions and
inflammation
Hermansson et al., 2011
ApoE-null mice DCs loaded with apoB peptides
(p2, p45, and p210)
50% decrease in plaque development Pierides et al., 2013
apo, apolipoprotein; FoxP3, forkhead box P3; LDL, low density lipoprotein; LDLR, LDL receptor; MDA-LDL, malonaldehyde-modified LDL; NZW, New Zealand White;
oxLDL, oxidized LDL; Tregs, regulatory T cells.
Vα14 subpopulation of NKT cells that were likely to be stimulated
by circulating endogenic lipoproteins in the atherosclerosis-prone
animals (Rogers et al., 2008). Thus, such an approach may offer a
tool for dissecting the contributions of individual subpopulations
of particular immune cells to the process of atherogenesis. In the
future, developing immune vaccines on the basis of specific sub-
sets of DCs should be helpful for selective depletion of deleterious
proatherogenic populations of effector cells such as Th1 and Th17
cells and induction of immunosuppressive anti-inflammatory
Tregs (Van Brussel et al., 2013).
CONCLUDING REMARKS
It is appreciated nowadays that atherosclerosis is a chronic
destruction of aortic and arterial walls, with a marked involve-
ment of inflammation (Hansson and Hermansson, 2011;
Tuttolomondo et al., 2012). DCs are recognized as key players
in the induction of inflammatory response in the atheroscle-
rotic plaque. It has become known that T cell activation occurs
after a cell-to-cell-contact between a DC and a naïve T cells
and by stimulation of the proinflammatory cytokines secreted
by mature DCs. A proinflammatory function of mature DCs
may be suppressed by a special subclass of T cells, namely by
Tregs. On the other hand, immature DCs possess tolerogenic anti-
inflammatory properties by leading naïve T cells to anergy or
apoptosis and by inducing Tregs. Thus, depending on the matu-
ration stage, DCs play a double role in atherogenesis: mature DCs
display proatherogenic features whereas immature DCs seem to
be anti-atherogenic. Since immature DCs are capable to induce
Tregs and inhibit the inflammatory reaction in the atheroscle-
rotic lesion, the development of strategies for the induction of
tolerogenic DCs may be of great therapeutic promise.
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